You are here: Welcome » Steven and Michele Kirsch Foundation

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
steven_and_michele_kirsch_foundation [2023/03/13 17:24]
liam 		steven_and_michele_kirsch_foundation [2023/03/13 17:45] (current)
liam
Line 16: Line 16:
  
 Between October 1999 and April 2001, the foundation partnered with [[CoreMatter]] (formerly known as AllCharities.com) and helped establish the use of the Internet as a charitable giving vehicle. The partnership ended shortly thereafter and CoreMatter ceased operations.((//Initiatives.// Kirsch Foundation. Retrieved March 11, 2023, from http://archive.today/2023.03.11-234424/https://www.kirschfoundation.org/who/initiatives.html)) Between October 1999 and April 2001, the foundation partnered with [[CoreMatter]] (formerly known as AllCharities.com) and helped establish the use of the Internet as a charitable giving vehicle. The partnership ended shortly thereafter and CoreMatter ceased operations.((//Initiatives.// Kirsch Foundation. Retrieved March 11, 2023, from http://archive.today/2023.03.11-234424/https://www.kirschfoundation.org/who/initiatives.html))
 +
 +In 2000, the foundation invested in [[pharmaceutical_companies:Targesome]], a biopharmaceutical company engaged in the development of proprietary receptor-targeted agents to treat and diagnose cancer and other diseases.((Kirsch, S. //Targesome donation.// SKirsch. Retrieved March 11, 2023, from http://archive.today/2023.03.11-234238/https://www.skirsch.com/charity/medical/targesome_donation.htm)) The company initiated a project with [[pharmaceutical_companies:Merck]] which would have seen the companies co-develop a cancer treatment. Targesome's founder published a paper on the company's work in June 2002 titled //Tumor Regression by Targeted Gene Delivery to the Neovasculature//.((Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., & Cheresh, D. A. (2002). //Tumor Regression by Targeted Gene Delivery to the Neovasculature.// Science, 296(5577), 2404–2407. https://doi.org/10.1126/science.1070200))
  
 In April 2001, the foundation made a $250,000 investment in [[LearnNow]]. After the company was acquired in July 2001 by [[Edison Schools]], the foundation sold off the majority of its stake. In April 2001, the foundation made a $250,000 investment in [[LearnNow]]. After the company was acquired in July 2001 by [[Edison Schools]], the foundation sold off the majority of its stake.
Back to top